BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 11 Oct 2019 Planned End Date changed from 28 Apr 2022 to 31 Dec 2021.
- 11 Oct 2019 Planned primary completion date changed from 28 Apr 2022 to 30 Nov 2020.
- 16 Aug 2019 This trial was completed in Czech Republic according to European Clinical Trials Database record